Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR
Aminopyridines
/ administration & dosage
Androstadienes
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Biomarkers, Tumor
Breast Neoplasms
/ drug therapy
Dose-Response Relationship, Drug
Everolimus
/ administration & dosage
Female
Follow-Up Studies
Humans
Middle Aged
Postmenopause
Prognosis
Purines
/ administration & dosage
Receptor, ErbB-2
/ metabolism
Receptors, Estrogen
/ metabolism
Receptors, Progesterone
/ metabolism
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 12 2020
15 12 2020
Historique:
received:
20
03
2020
revised:
04
07
2020
accepted:
25
09
2020
pubmed:
2
10
2020
medline:
15
12
2021
entrez:
1
10
2020
Statut:
ppublish
Résumé
Report results of the phase Ib dose-escalation/expansion study of triplet therapy with cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor (ribociclib), mTOR inhibitor (everolimus), and endocrine therapy (exemestane). Postmenopausal women with hormone receptor-positive (HR Patients ( Triplet therapy with endocrine therapy and mTOR and CDK4/6 inhibition provides clinical benefit and an acceptable safety profile in previously treated postmenopausal women with HR
Identifiants
pubmed: 32998962
pii: 1078-0432.CCR-20-1068
doi: 10.1158/1078-0432.CCR-20-1068
pmc: PMC8489181
mid: NIHMS1732896
doi:
Substances chimiques
Aminopyridines
0
Androstadienes
0
Biomarkers, Tumor
0
Purines
0
Receptors, Estrogen
0
Receptors, Progesterone
0
Everolimus
9HW64Q8G6G
Receptor, ErbB-2
EC 2.7.10.1
exemestane
NY22HMQ4BX
ribociclib
TK8ERE8P56
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6417-6428Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
JAMA Oncol. 2018 Jul 1;4(7):977-984
pubmed: 29566104
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
Front Oncol. 2019 Jul 23;9:666
pubmed: 31396487
N Engl J Med. 2016 Nov 3;375(18):1738-1748
pubmed: 27717303
J Clin Oncol. 2019 May 10;37(14):1169-1178
pubmed: 30807234
J Clin Oncol. 2016 Sep 1;34(25):3069-103
pubmed: 27217461
Cancer Res. 2016 Apr 15;76(8):2301-13
pubmed: 27020857
N Engl J Med. 2012 Feb 9;366(6):520-9
pubmed: 22149876
Med Sci Monit. 2019 Jan 03;25:77-86
pubmed: 30605443
J Clin Oncol. 2018 Aug 20;36(24):2465-2472
pubmed: 29860922
Curr Opin Pharmacol. 2003 Aug;3(4):371-7
pubmed: 12901945
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Ann Oncol. 2019 Nov 1;30(11):1842
pubmed: 31407010
Oncol Rev. 2017 May 16;11(1):323
pubmed: 28584571
Crit Rev Oncol Hematol. 2017 Jun;114:91-101
pubmed: 28477750
Lancet Oncol. 2018 Jul;19(7):904-915
pubmed: 29804902
N Engl J Med. 2019 Jul 25;381(4):307-316
pubmed: 31166679
Clin Cancer Res. 2016 Dec 1;22(23):5696-5705
pubmed: 27542767
Annu Rev Med. 2011;62:233-47
pubmed: 20887199
Clin Pharmacol Ther. 2018 Aug;104(2):374-383
pubmed: 29134635
N Engl J Med. 2020 Feb 6;382(6):514-524
pubmed: 31826360
J Natl Compr Canc Netw. 2017 Apr;15(4):433-451
pubmed: 28404755
Ann Oncol. 2018 Aug 1;29(8):1634-1657
pubmed: 30032243
Clin Pharmacokinet. 2004;43(2):83-95
pubmed: 14748618
Am J Cancer Res. 2018 Dec 01;8(12):2359-2376
pubmed: 30662797
Clin Cancer Res. 2004 Mar 15;10(6):1943-8
pubmed: 15041710
Ann Oncol. 2018 Jul 1;29(7):1541-1547
pubmed: 29718092
Clin Pharmacol Ther. 2020 Sep;108(3):575-585
pubmed: 32557601
Breast Cancer Res Treat. 2019 Apr;174(3):615-625
pubmed: 30607633